Literature DB >> 8151292

Characterization of the herpes simplex virus type 1 strain 17+ neurovirulence gene RL1 and its expression in a bacterial system.

E A McKie1, R G Hope, S M Brown, A R MacLean.   

Abstract

The DNA sequence of herpes simplex virus type 1 (HSV-1) strain 17+ in the region coding for the polypeptide ICP34.5 predicts a protein of 248 amino acids with a proposed M(r) of 26,158. The entire RL1 open reading frame was cloned into the expression vector pET8c to enable over-expression of ICP34.5 in Escherichia coli. The expressed protein was partially purified and used as an immunogen to produce a polyclonal antiserum in rabbits. Construction of an ICP34.5 null mutant (1771), demonstrated that the predicted open reading frame for ICP34.5 in strain 17+ is correct and confirmed that HSV-1 strain 17+ ICP34.5 specifically determines neurovirulence. The specificity of the anti-serum directed against the E. coli-expressed ICP34.5 was defined by Western blotting of wild-type and RL1-negative infected cell extracts.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151292     DOI: 10.1099/0022-1317-75-4-733

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

Review 1.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

2.  Activation of NF-κB in CD8+ dendritic cells Ex Vivo by the γ134.5 null mutant correlates with immunity against herpes simplex virus 1.

Authors:  Huali Jin; Yijie Ma; Zhipeng Yan; Bellur S Prabhakar; Bin He
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Signals that dictate nuclear, nucleolar, and cytoplasmic shuttling of the gamma(1)34.5 protein of herpes simplex virus type 1.

Authors:  Guofeng Cheng; Marie-Elena Brett; Bin He
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

4.  A virus with a mutation in the ICP4-binding site in the L/ST promoter of herpes simplex virus type 1, but not a virus with a mutation in open reading frame P, exhibits cell-type-specific expression of gamma(1)34.5 transcripts and latency-associated transcripts.

Authors:  L Y Lee; P A Schaffer
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34.

Authors:  S M Brown; A R MacLean; E A McKie; J Harland
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

6.  Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1.

Authors:  J Chou; J J Chen; M Gross; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

7.  Differential response of human cells to deletions and stop codons in the gamma(1)34.5 gene of herpes simplex virus.

Authors:  J Chou; A P Poon; J Johnson; B Roizman
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Neurovirulent factor ICP34.5 uniquely expressed in the herpes simplex virus type 1 Delta gamma 1 34.5 mutant 1716.

Authors:  Holly A Holman; Alasdair R MacLean
Journal:  J Neurovirol       Date:  2008-01       Impact factor: 2.643

9.  Selective vulnerability of mouse CNS neurons to latent infection with a neuroattenuated herpes simplex virus-1.

Authors:  S Kesari; V M Lee; S M Brown; J Q Trojanowski; N W Fraser
Journal:  J Neurosci       Date:  1996-09-15       Impact factor: 6.167

10.  The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins.

Authors:  June Harland; Paul Dunn; Euan Cameron; Joe Conner; S Moira Brown
Journal:  J Neurovirol       Date:  2003-08       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.